CRNX — Crinetics Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $3.91bn
- $2.72bn
- $1.04m
- 53
- 10
- 31
- 20
Annual income statement for Crinetics Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.071 | 1.08 | 4.74 | 4.01 | 1.04 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 75 | 109 | 173 | 227 | 340 |
| Operating Profit | -75 | -108 | -168 | -223 | -339 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -73.8 | -108 | -163 | -209 | -298 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -73.8 | -108 | -163 | -209 | -298 |
| Equity in Affiliates | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -73.8 | -108 | -164 | -215 | -298 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -73.8 | -108 | -164 | -215 | -298 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.42 | -2.8 | -3.15 | -3.69 | -3.69 |